ProMIS Neurosciences (PMN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
20 May, 2026Opening remarks and agenda
Meeting chaired by the CEO, with appointments of recording secretary and scrutineer.
Agenda included presentation of annual financial statements, election of seven directors, appointment of auditor, and approval of an amendment to the 2025 Stock Option and Incentive Plan.
Financial performance review
Audited financial statements for the year ended December 31, 2025, and auditor's report were presented and accepted.
Board and executive committee updates
Seven director nominees were presented, all consenting to stand for election.
No nominations were received for persons other than those named in the proxy statement.
Partial view of Summaries dataset, powered by Quartr API
Latest events from ProMIS Neurosciences
- Interim PRECISE-AD trial data showed strong safety, biomarker progress, and cash runway through 2027.PMN
Q2 2026 - Blinded interim data show strong safety and early biomarker improvement in Alzheimer's patients.PMNStudy result
- Interim phase I-B Alzheimer's data expected early Q3, with strong funding and pipeline momentum.PMN2026 Bloom Burton & Co. Healthcare Investor Conference
- Interim safety and biomarker data for a selective Alzheimer's antibody are expected in early Q3.PMNJefferies Global Healthcare Conference 2026
- Q1 2026 net loss $8.2M, $175M PIPE closed, Alzheimer's trial milestones on track.PMNQ1 2026
- PMN310 targets toxic amyloid-beta in Alzheimer's, with pivotal data expected in 2026.PMNInvestor presentation
- Phase 1b Alzheimer's trial fully enrolled; data and platform validation expected this year.PMNGuggenheim Securities Emerging Outlook: Biotech Summit 2026
- Shareholders will vote on board elections, auditor ratification, and expanding the stock option plan.PMNProxy filing
- Election of directors, auditor ratification, and stock plan amendment up for vote in May 2026.PMNProxy filing